Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Galli

Showing results (341-350 of 354) with videos related to

Pageof 36
Sort By:
The Oncologist|October 5, 2023
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort StudyFederica Pecci, Luca Cantini, Valeria Cognigni, et al.
Clinical Lung Cancer|August 2, 2021
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon HistologySara Manglaviti, Marta Brambilla, Diego Signorelli, et al.
Cancers|January 21, 2022
Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with ImmunotherapyArsela Prelaj, Mattia Boeri, Alessandro Robuschi, et al.
Physical Biology|December 6, 2017
Roadmap on semiconductor-cell biointerfacesBozhi Tian, Shuai Xu, John A Rogers, et al.
Lung Cancer (Amsterdam, Netherlands)|November 2, 2023
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitorsSara Manglaviti, Marta Bini, Giulia Apollonio, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2022
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysisGiuseppe Viscardi, Antonino C Tralongo, Francesco Massari, et al.
Therapeutic Advances in Medical Oncology|August 4, 2022
Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer centerGiovanni Fucà, Mara Lecchi, Chiara Maura Ciniselli, et al.
Lung Cancer (Amsterdam, Netherlands)|December 10, 2025
Treatment response after induction therapy in advanced thymic tumors: results from the Italian nationwide TYME databaseGiovanni Leuzzi, Federica Sabia, Claudia Proto, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 24, 2023
STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further LinesClaudia Proto, Sara Manglaviti, Giuseppe Lo Russo, et al.
Frontiers in Oncology|February 9, 2023
Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patientsArsela Prelaj, Edoardo Gregorio Galli, Vanja Miskovic, et al.
Pageof 36

Showing results (341-350 of 354) with videos related to

Sort By:
Pageof 36
The Oncologist|October 5, 2023
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort StudyFederica Pecci, Luca Cantini, Valeria Cognigni, et al.
Clinical Lung Cancer|August 2, 2021
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon HistologySara Manglaviti, Marta Brambilla, Diego Signorelli, et al.
Cancers|January 21, 2022
Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with ImmunotherapyArsela Prelaj, Mattia Boeri, Alessandro Robuschi, et al.
Physical Biology|December 6, 2017
Roadmap on semiconductor-cell biointerfacesBozhi Tian, Shuai Xu, John A Rogers, et al.
Lung Cancer (Amsterdam, Netherlands)|November 2, 2023
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitorsSara Manglaviti, Marta Bini, Giulia Apollonio, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2022
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysisGiuseppe Viscardi, Antonino C Tralongo, Francesco Massari, et al.
Therapeutic Advances in Medical Oncology|August 4, 2022
Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer centerGiovanni Fucà, Mara Lecchi, Chiara Maura Ciniselli, et al.
Lung Cancer (Amsterdam, Netherlands)|December 10, 2025
Treatment response after induction therapy in advanced thymic tumors: results from the Italian nationwide TYME databaseGiovanni Leuzzi, Federica Sabia, Claudia Proto, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 24, 2023
STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further LinesClaudia Proto, Sara Manglaviti, Giuseppe Lo Russo, et al.
Frontiers in Oncology|February 9, 2023
Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patientsArsela Prelaj, Edoardo Gregorio Galli, Vanja Miskovic, et al.
Pageof 36